Prognostic value of body mass index in locally advanced breast cancer

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1718-1725

  Dawood, Shaheenah ^a,b   Broglio, Kristine ^a   Gonzalez Angulo, Ana M ^a   Kau, Shu Wan ^a   Islam, Rabiul ^a   Hortobagyi, Gabriel N ^a   Cristofanilli, Massimo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DUBAI HOSPITAL   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OBESITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; UNDERWEIGHT;

ADULT; AGED; BODY MASS INDEX; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM METASTASIS; OBESITY; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS;

EID: 41549103014     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1479     Document Type: Article

References (29)

1. Schwartsmann G. Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol 2001;19:118-24.
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:1014-24.
3. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-16.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177-82.
5. van den Brandt P, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height,weight, and breast cancer risk. Am J Epidemiol 2000;152:514-27.
6. Morimoto LM, White E, Chen Z, et al. Obesity, body size and risk of post-menopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
7. Goodwin PJ, Boyd NF. Body size and breast cancer prognosis: A critical review of the evidence. Breast Cancer Res Treat 1990;16:205-14.
8. Chelbowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-43.
9. Holmberg L, Lund E, Bergstrom R, Adami HO, Meirik O. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994;30:351-4.
10. Lethaby AE, Mason BH, Harvey VJ, Holdaway IM. Survival of women with node negative breast cancer in the Auckland region. N Z Med J 1996;109:330-3.
11. Zumoff B, Dasgupta I. Relationship between body weight and the incidence of positive nodes at mastectomy in breast cancer. J Surg Oncol 1983;22:217-20.
12. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL. Body mass and stage of breast cancer at diagnosis. In J Cancer 2002;98:279-83.
13. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol 1998;16:3731-5.
14. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 2000;64:157-63.
15. Koh EH, Buzdar AU, Ames FC, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach - M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 1990;27:94-100.
16. Ueno NT, Buzdar AU, Singeltary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D Anderson Cancer Center. Cancer Chemother Pharmacol 1997;40:321-9.
17. Green FL, Page DL, Flemming ID, et al. Breast. In: AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002. p. 225-81.
18. Gooley TZ, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks. Stat Med 1999;18:695-706.
19. Berclaz G, Li S, Price KN, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004;15:875-84.
20. Dignam JJ, Wieand K, Johnson K, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early stage breast cancer. J Natl Cancer Inst 2003;95:1467-76.
21. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in post-menopausal women. J Natl Cancer Inst 2003;95:1218-26.
22. Ivandic A, Prpic-Krizevac I, Sucic M, Juric M. Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity. Metabolism 1998;47:13-9.
23. Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat 2002;74:65-76.
24. Ross DP, Gilhooly EM, Nixon DW. Adverse effects of obesity on breast cancer prognosis, and the biological actions of leptin (review). Int J Oncol 2002;21:1285-92.
25. Huang L, Li C. Leptin. A multifunctional hormone. Cell Res 2000;10:81-92.
26. Fung TT, Rimm EB, Spiegelman D, et al. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr 2001;73:61-7.
27. Goodwin PJ, Ennis M, Fantus IG, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol 2005;23:6037-42.
28. Denmark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001;19:2381-9.
29. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006;98:1767-76.